Ginsenoside Rg1 competitively inhibits 2,3,7,8-tetrachlorodibenzodioxin (TCDD)-induced cytochrome P450 1A1 mRNA transcription by regulating aryl hydrocarbon receptor nuclear translocation, and it is a potent AhR agonist, so it can become a potentially effective drug for the prevention of TCDD-related liver injury [37]. The gene discussed is CYP1A1; the disease is injury.